Ezivac%2525252525252525252525252525252525252525252525252525252525252525252520enema

# Ezivac Enema > **Assumption:** “Ezivac enema” refers to a **rectal sodium phosphate enema** (commonly dibasic sodium phosphate 7 g + monobasic sodium phosphate 19 g in 118 mL). Verify the product label and local prescribing information because formulations and concentrations may vary. ## Overview - **Drug class:** Saline/osmotic laxative. - **Route:** Rectal only; do **not** administer orally. - Draws water into the colon and stimulates evacuation. - Usual onset: **1–5 minutes**, although response may take longer. - Intended for **short-term relief of occasional constipation** or bowel evacuation before procedures. ## Primary Indications - Occasional constipation with rectal stool burden. - Bowel evacuation before selected diagnostic or surgical procedures, according to local protocol. ## Adult Dosing - **Adults and adolescents ≥12 years:** Instill **1 bottle (approximately 118 mL) rectally once**. - **Maximum:** **1 dose in 24 hours**. Do not use for more than **3 consecutive days** without medical advice. - Do not use a second enema if the first is ineffective unless specifically directed by a clinician. ## Pediatric Dosing For standard sodium phosphate enema products: - **Children 5–11 years:** **½ bottle (approximately 59 mL) rectally once**. - **Children 2–4 years:** **¼ bottle (approximately 29.5 mL) rectally once**. - **Children <2 years:** **Do not use** unless specifically prescribed by a specialist. - **Maximum:** One dose in 24 hours; avoid repeated dosing. - Pediatric use requires confirmation of the product concentration and appropriate applicator volume. Do not force insertion or administration. ## Dose Adjustments - **Renal impairment:** No reliable dose reduction prevents toxicity; **avoid in moderate-to-severe renal impairment, acute kidney injury, or significant renal disease** unless specialist-directed. - **Older adults, dehydration, heart failure, or electrolyte disorders:** Prefer safer alternatives when possible; if used, use only one dose with careful monitoring. - **Children:** Use age-specific volumes above; do not extrapolate adult dosing. - **Bowel-preparation protocols:** Dosing may differ and should follow the local gastroenterology/surgical protocol. ## Contraindications - Hypersensitivity to product ingredients. - Suspected or known **bowel obstruction, ileus, perforation, or severe fecal impaction** without medical evaluation. - Severe abdominal pain, nausea, or vomiting of unexplained cause. - Active proctitis, significant rectal bleeding, or anal/rectal injury. - Significant renal impairment, dehydration, hyperphosphatemia, or clinically important electrolyte abnormalities. - Uncontrolled heart failure or high risk of fluid/electrolyte disturbance. - Use in children **under 2 years** unless specifically prescribed. - Avoid routine use in inflammatory bowel disease or recent colorectal surgery unless directed by a clinician. ## Adverse Effects ### Common - Rectal irritation, burning, cramping, bloating. - Urgency or diarrhea. - Mild abdominal discomfort. ### Serious - **Hyperphosphatemia, hypocalcemia, hypokalemia, hypernatremia**, metabolic acidosis. - Dehydration, hypotension, syncope, acute kidney injury. - Cardiac arrhythmias, seizures, confusion, or tetany from severe electrolyte disturbance. - Rectal mucosal injury, ulceration, or perforation, particularly with forceful insertion or repeated use. - Rarely, severe phosphate nephropathy. Seek urgent care for severe abdominal pain, persistent vomiting, rectal bleeding, marked weakness, confusion, fainting, reduced urine output, seizures, or no bowel movement with worsening symptoms. ## Key Drug Interactions Use caution or avoid concurrent use with: - **Diuretics**, especially loop or thiazide diuretics. - **ACE inhibitors, ARBs, and renin inhibitors.** - **NSAIDs**, including ibuprofen and naproxen. - **Lithium.** - Other laxatives, bowel preparations, or phosphate-containing products. - Drugs affecting renal function or electrolytes, including calcineurin inhibitors. - Medications containing calcium, magnesium, or aluminum may have altered absorption or additive electrolyte effects. Separate other rectally administered medicines and oral medicines when feasible; rectal evacuation may reduce absorption. Patients taking narrow-therapeutic-index medicines or multiple nephrotoxic drugs should consult a clinician before use. ## Monitoring For a single low-risk dose, routine laboratory monitoring is usually unnecessary. Monitor or obtain medical review in high-risk patients: - Renal function: serum creatinine and estimated GFR. - Electrolytes: sodium, potassium, calcium, phosphate, and bicarbonate. - Hydration status, blood pressure, urine output, and mental status. - Bowel response and signs of obstruction or rectal injury. - In children, older adults, or patients with renal/cardiac disease: have a lower threshold for laboratory assessment. Avoid use if the patient is dehydrated or unable to maintain oral fluid intake. ## Clinical Pearls - Confirm the **active ingredients and volume** before dosing; “Ezivac” labeling may vary by country. - Lubricate the applicator and insert gently. **Never force** the applicator. - Do not administer orally. - Encourage appropriate oral hydration unless fluid-restricted. - Avoid repeated enemas; sodium phosphate toxicity can occur after a single dose in vulnerable patients. - If constipation persists beyond several days, recurs frequently, or is associated with bleeding, weight loss, severe pain, vomiting, or fever, evaluate the underlying cause. - For routine constipation, oral polyethylene glycol is often safer and more appropriate than phosphate enemas. - **No response within 30 minutes, worsening pain, or significant rectal bleeding warrants medical evaluation rather than repeat dosing.** *Educational information only; verify the current product label, concentration, local pediatric protocol, contraindications, and prescribing information before use.*